Back to Search
Start Over
Three‐year clinical outcomes after dual‐therapy COMBO stent placement: Insights from the REMEDEE registry
- Source :
- Catheterization and Cardiovascular Interventions, 94, 342-347, Catheterization and Cardiovascular Interventions, 94, 3, pp. 342-347, Catheterization and cardiovascular interventions, 94(3), 342-347. Wiley-Liss Inc.
- Publication Year :
- 2018
- Publisher :
- Wiley, 2018.
-
Abstract
- Background: The bio-engineered COMBO stent (OrbusNeich Medical BV, The Netherlands) is a dual-therapy pro-healing stent. This novel technology may allow a shorter duration of dual antiplatelet therapy (DAPT) after stenting. We present the first 3 year clinical outcomes of patients treated with COMBO stent. Methods and results: The prospective, multicenter, investigator-initiated, all-comers REMEDEE Registry evaluates clinical outcomes after COMBO stent treatment. A 1,000 patients were enrolled between June 2013 and March 2014. Patients had a mean of 65 years ±11, 26% of the patients were females and 18% diabetics. More than 50% of patients presented with acute coronary syndrome, 60% of treated lesions were AHA/ACC lesion type B2 or C. Target lesion failure (TLF) at 3 year follow-up occurred in 10.7% of patients (N = 105). The separate components cardiac death, target vessel myocardial infarction and target lesion revascularization occurred in 4.1%, 2.0%, and 7.1%, respectively of patients. Definite stent thrombosis (ST) was observed in 0.7% of all patients. At 3-year follow-up there were only 73 patients taking DAPT. Conclusions: At 3-year follow-up, patients treated with COMBO stent in the present large prospective all-comers cohort, continue to show good clinical outcomes. Clinicaltrials.gov identifier: NCT01874002. Condensed abstract: The COMBO stent is a sirolimus-eluting stent with a luminal anti-CD34-antibody layer, that binds endothelial progenitor cells. These cells can differentiate to endothelial cells and stimulate early endothelialization of the stent. The REMEDEE Registry is the first large, multicenter, prospective, cohort study evaluating the clinical outcomes of 1,000 all-comers patients treated with COMBO stent. Target lesion failure at 3 year follow-up was 10.7% and the rate of definite ST was 0.7%.
- Subjects :
- Male
Target lesion
medicine.medical_specialty
Acute coronary syndrome
Time Factors
interventional devices/innovation
medicine.medical_treatment
Vascular damage Radboud Institute for Health Sciences [Radboudumc 16]
030204 cardiovascular system & hematology
Coronary artery disease
03 medical and health sciences
All institutes and research themes of the Radboud University Medical Center
0302 clinical medicine
Risk Factors
medicine
Humans
Radiology, Nuclear Medicine and imaging
Prospective Studies
Registries
030212 general & internal medicine
Myocardial infarction
Acute Coronary Syndrome
Aged
stent thrombosis
business.industry
Coronary Thrombosis
percutaneous coronary intervention
Percutaneous coronary intervention
Stent
General Medicine
Middle Aged
equipment and supplies
medicine.disease
Surgery
Europe
Treatment Outcome
Drug-eluting stent
Female
Stents
Cardiology and Cardiovascular Medicine
business
drug eluting stent
coronary artery disease
stent restenosis
Cohort study
Subjects
Details
- ISSN :
- 1522726X and 15221946
- Volume :
- 94
- Database :
- OpenAIRE
- Journal :
- Catheterization and Cardiovascular Interventions
- Accession number :
- edsair.doi.dedup.....eee7ed398a41977fbd9eccb684849836